Medovir (Aciclovir)

Aciclovir is a nucleoside analogue that is first phosphorylated by the viral thymidine kinase enzyme. Subsequent cellular phosphorylation converts it to aciclovir triphosphate, which competitively inhibits viral DNA polymerase. This blocks viral DNA chain elongation, preventing replication of herpes simplex and varicella‑zoster viruses while sparing uninfected cells.

The appropriate dose of Medovir is determined by the prescribing healthcare professional based on the specific infection, patient age, renal function, and other clinical factors. Dosage regimens can vary widely, so patients should follow the exact instructions provided by their prescriber and not adjust the dose on their own.

Safety data for aciclovir in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing women. If treatment is deemed necessary, it should be used under close medical supervision.

To request Medovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Medovir (aciclovir) is a first‑generation antiviral that is less bioavailable than newer agents such as valacyclovir or famciclovir, which are prodrugs offering higher systemic exposure and less frequent dosing. However, aciclovir remains a well‑studied, cost‑effective option for many herpes infections, especially where generic availability is important.

Medovir should be stored at ambient temperature below 25 °C. Keep the tablets in their original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed. Do not store in a refrigerator or freezer unless the manufacturer specifies otherwise.

Medovir is taken orally, usually with a full glass of water. The tablets can be swallowed with or without food, unless the prescribing information advises otherwise. Patients should follow the dosing schedule prescribed by their healthcare provider and complete the full course of therapy even if symptoms improve.

Serious adverse reactions, although rare, include acute renal failure, severe allergic responses such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, hematologic abnormalities like thrombocytopenia or neutropenia, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience rash, swelling, difficulty breathing, or signs of kidney dysfunction.

Medovir is contraindicated in individuals with known hypersensitivity to aciclovir or any of its excipients. Caution is advised for patients with severe renal impairment, as dose adjustment may be required. It should also be used carefully in immunocompromised patients, and only under medical supervision during pregnancy or lactation.